These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29199852)

  • 1. Bleeding with oral anticoagulant dabigatran is highly associated with occult cancers in atrial fibrillation patients.
    Koike H; Fujino T; Koike M; Yao S; Akitsu K; Shinohara M; Yuzawa H; Suzuki T; Ikeda T
    Future Cardiol; 2018 Jan; 14(1):27-36. PubMed ID: 29199852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation.
    Flack KF; Desai J; Kolb JM; Chatterjee P; Wallentin LC; Ezekowitz M; Yusuf S; Connolly S; Reilly P; Brueckmann M; Ilgenfritz J; Aisenberg J
    Clin Gastroenterol Hepatol; 2017 May; 15(5):682-690. PubMed ID: 27765728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dabigatran according to age in atrial fibrillation.
    Lauw MN; Eikelboom JW; Coppens M; Wallentin L; Yusuf S; Ezekowitz M; Oldgren J; Nakamya J; Wang J; Connolly SJ
    Heart; 2017 Jul; 103(13):1015-1023. PubMed ID: 28213368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Predicted Rate and Associated Factors of Dabigatran-induced Bleeding Events in Malaysian Patients with Non-Valvular Atrial Fibrillation.
    Beshir SA; Yap LB; Sim S; Chee KH; Lo YL
    J Pharm Pharm Sci; 2017; 20(1):365-377. PubMed ID: 29145930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
    Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
    Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.
    Stabile E; Izzo R; Rozza F; Losi MA; Coscioni E; Trimarco B
    High Blood Press Cardiovasc Prev; 2016 Jun; 23(2):115-22. PubMed ID: 27207360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
    Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate.
    Chang YT; Hu YF; Liao JN; Chern CM; Lin YJ; Chang SL; Wu CH; Sung SH; Wang KL; Lu TM; Chao TF; Lo LW; Hsu LC; Chung CP; Chang PM; Hsu WH; Chiou CW; Chen SA
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):389-95. PubMed ID: 26991859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran.
    Kolb JM; Flack KF; Chatterjee-Murphy P; Desai J; Wallentin LC; Ezekowitz M; Connolly S; Reilly P; Brueckmann M; Ilgenfritz J; Aisenberg J
    Dig Dis Sci; 2018 Jul; 63(7):1878-1889. PubMed ID: 29582237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review.
    Milling TJ; Fromm C; Ganetsky M; Pallin DJ; Cong J; Singer AJ
    Ann Emerg Med; 2017 May; 69(5):531-540. PubMed ID: 28196608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy.
    Lauffenburger JC; Rhoney DH; Farley JF; Gehi AK; Fang G
    Pharmacotherapy; 2015 Jun; 35(6):560-8. PubMed ID: 26044889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
    Beyer-Westendorf J; Ebertz F; Förster K; Gelbricht V; Michalski F; Köhler C; Werth S; Endig H; Pannach S; Tittl L; Sahin K; Daschkow K; Weiss N
    Thromb Haemost; 2015 Jun; 113(6):1247-57. PubMed ID: 25739533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran Use in the Real World: A Multihospital System Experience.
    Kimmons LA; Kabra R; Davis M; Segars BV; Oliphant CS
    J Pharm Pract; 2014 Aug; 27(4):384-8. PubMed ID: 24319080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabigatran use in elderly patients with atrial fibrillation.
    Avgil-Tsadok M; Jackevicius CA; Essebag V; Eisenberg MJ; Rahme E; Behlouli H; Pilote L
    Thromb Haemost; 2016 Jan; 115(1):152-60. PubMed ID: 26354766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation.
    Yavuz B; Ayturk M; Ozkan S; Ozturk M; Topaloglu C; Aksoy H; Şabanoglu C; Tanalp AC; Dal K; Ata N; Yavuz BB
    J Thromb Thrombolysis; 2016 Oct; 42(3):399-404. PubMed ID: 27085540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding events associated with a low dose (110 mg) versus a high dose (150 mg) of dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Chaudhary N; Yuan J
    BMC Cardiovasc Disord; 2017 Mar; 17(1):83. PubMed ID: 28298191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence, effectiveness and safety of dabigatran in "real-world" Chinese patients with nonvalvular atrial fibrillation.
    Rong G; Huang Y; Wang L; Liang H; Wang H
    Heart Vessels; 2020 Jul; 35(7):977-984. PubMed ID: 32006091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.